The upregulation of PGC1α induce overexpression of OXPHOS gene set, by providing a structural basis for enhanced OXPHOS in multiple myeloma cells; SR18292, a new PGC1α inhibitor, exerts potent antimyeloma effects becoming a new therapeutic strategy [281]. This evidence concerns the gene PPARGC1A and plasma cell myeloma.